Current understanding in the management of sickle cell disease

Hemoglobin

Volumn 33, Issue SUPPL. 1, 2009, Pages

  Inati, Adlette ^a   Chabtini, Lola ^a   Mounayar, Marwan ^a   Taher, Ali ^b  

^a RAFIC HARIRI UNIVERSITY HOSPITAL   (Lebanon)

^b AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

Genotype phenotype correlation; Hydroxyurea; Sickle cell disease; Transfusions

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BUTYRIC ACID DERIVATIVE; CLOTRIMAZOLE; DEFERASIROX; HYDROXYUREA; PENICILLIN G;

BRAIN INFARCTION; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; CYTOLOGY; DISEASE SEVERITY; EVENT FREE SURVIVAL; GENE THERAPY; GENOTYPE PHENOTYPE CORRELATION; HEALTH CARE PERSONNEL; HUMAN; IRON OVERLOAD; MOLECULAR BIOLOGY; MORBIDITY; MORTALITY; OVERALL SURVIVAL; PATHOPHYSIOLOGY; PROPHYLAXIS; SEPTICEMIA; SICKLE CELL ANEMIA; STREPTOCOCCUS PNEUMONIA; STROKE;

ANEMIA, SICKLE CELL; CLINICAL TRIALS AS TOPIC; DISEASE MANAGEMENT; HUMANS; TREATMENT OUTCOME;

EID: 73949143085     PISSN: 03630269     EISSN: 1532432X     Source Type: Journal    
DOI: 10.3109/03630260903347682     Document Type: Conference Paper

References (34)

1. Herrick JB. Peculiar elongated and sickled-shaped red blood corpuscles in a case of severe anemia. Arch Intern Med. 1910;6:517-521.
2. Pauling L, Itano HA, Singer SJ, Wells IC. Sickle cell anemia: a molecular disease. Science. 1949; 110:543-548.
3. Ingram VM. Gene mutations in human haemoglobin: the chemical difference between normal and sickle haemoglobin. Nature. 1957;180:326-328.
4. Perutz MF, Rossmann MG, Cullis AF, et al. Structure of haemoglobin: a three-dimensional Fourier synthesis at 5•5Å resolution obtained by X-ray analysis. Nature. 1960;185:416-422.
5. Watson J, Stahman AW, Billelo FP. The significance of the paucity of sickle cells in newborn Negro infants. Am J Med Sci. 1948;215:419-423.
6. Stuart MJ, Nagel RL. Sickle-cell disease. Lancet. 2004;364:1343-1360.
7. Inati A, Koussa S, Taher A, Perrine S. Sickle cell disease: new insights into pathophysiology and treatment. Pediatr Ann. 2008;37(5):311-321.
8. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease: life expectancy and risk factors for early death. N Engl J Med. 1994;330:1639-1644.
9. Inati A, Taher A, Bou Alawi W, et al. Beta-globin gene cluster haplotypes and HbF levels are not the only modulators of sickle cell disease in Lebanon. Eur J Haematol. 2003;70:79-83.
10. Gaston MH, Verter JI, Woods G, et al. Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial. N Engl J Med. 1986;314:1593-1599.
11. Falletta JM, Woods GM, Verter JI, et al. Discontinuing penicillin prophylaxis in children with sickle cell anemia. Prophylactic penicillin study II. J Pediatr. 1995;127:685-690.
12. Vichinsky EP, Haberkern CM, Neumayr L, et al. A comparison of conservative and aggressive transfusion regimens in the perioperative management of sickle cell disease. The preoperative transfusion in sickle cell disease study group. N Engl J Med. 1995;333(4):206-213.
13. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on frequency of painful crises in sickle cell anemia. Investigators of the multicenter study of hydroxyurea in sickle cell anemia. N Engl J Med. 1995;332(2):1317-1322.
14. Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. J Am Med Assoc. 2003; 289(13):1645-1651.
15. Kinney TR, Helms RW, O'Branski EE, et al. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric hydroxyurea group. Blood. 1999;94(5): 1550-1554.
16. Hankins JS, Ware RE, Rogers ZR, et al. Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. Blood. 2005;106(7):2269-2275.
17. Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med. 1998;339:5-11.
18. Adams RJ, Brambilla D, Optimizing Primary Stroke Prevention in Sickle Cell Anemia (STOP 2) Trial Investigators. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med. 2005;353:2769-2778.
19. Aygun B, McMurray MA, Schultz WH, et al. Chronic transfusion practice for children with sickle cell anaemia and stroke. Br J Haematol. 2009;145(4):524-528.
20. Zimmerman SA, Schultz WH, Davis JS, et al. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood. 2004; 103(6):2039-2045.
21. Zimmerman SA, Schultz WH, Burgett S, Mortier NA, Ware RE. Hydroxyurea therapy lowers transcranial Doppler flow velocities in children with sickle cell anemia. Blood. 2007;110(3):1043-1047.
22. Sickle Cell Society. Standards for the Clinical Care of Adults with Sickle Cell Disease in the UK.London: Sickle Cell Society; 2008.
23. Ballas SK. Iron overload is a determinant of morbidity and mortality in adult patients with sickle cell disease. Semin Hematol. 2001;38(1 Suppl. 1):30-36.
24. Olivieri NF. Progression of iron overload in sickle cell disease. Semin Hematol. 2001;38(1 Suppl. 1):57-62.
25. Cohen AR, Martin MB. Iron chelation therapy in sickle cell disease. Semin Hematol. 2001;38 (1 Suppl. 1):69-72.
26. Inati A, Taha M, Musallam K, Ziade F, Rachkidi Y, Taher A. Magnetic resonance imaging R2 mapping accurately estimates iron overload in sickle cell disease patients. Haematologica. 2009;94(Suppl. 2): 511. Abs. 1285.
27. Elliott V, Ellen B, Ellen F, et al. Comparison of organ dysfunction in transfused patients with SCD or beta thalassemia. Am J Hematol. 2005;80:70-74.
28. Vichinsky E, Onyekwere O, Porter J, et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol. 2007; 136(3):501-508.
29. Voskaridou E, Douskou M, Terpos E, et al. Deferiprone as an oral iron chelator in sickle cell disease. Ann Hematol. 2005;84(7):434-440.
30. Walters MC, Storb R, Patience M, et al. Impact of bone marrow transplantation for symptomatic sickle cell disease: an interim report. Multicenter investigation of bone marrow transplantation for sickle cell disease. Blood. 2000;95(6):1918-1924.
31. Bernaudin F, Socie G, Kuentz M, et al.. Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease. Blood. 2007;110(7):2749-2756.
32. Panepinto JA, Walters MC, Carreras J, et al. Matched-related donor transplantation for sickle cell disease: report from the Center for International Blood and Transplant Research. Br J Haematol. 2007;137(5):479-485.
33. Quinn CT, Rogers ZR, Buchanan GR. Survival of children with sickle cell disease. Blood. 2004; 103(11):4023-4027.
34. Telfer P, Coen P, Chakravorty S, et al. Clinical outcomes in children with sickle cell disease living in England: a neonatal cohort in East London. Haematologica. 2007;92(7):905-912.